{"id":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","name":"MMI CMS ARTICLES","timestamp":1446799444935,"order":["84067e7e-f276-9580-7fb4-4079ed20b57c","8da11c82-f2d3-1081-a03c-4652cf514e26","5b76a55a-c1d5-b503-ce9d-e742a3335189","b0ac2533-1e85-8562-2481-1a2003cb2a6a","8abbc7d1-27f8-3389-a5dd-c123bcab089c","551abbb1-2377-fac5-a867-cb3fbd667dbe","8c2dac13-48ba-4b43-bccc-fc5ccb7882fd","7d2d21c9-9cce-bdcf-5415-133e4fc6705f"],"requests":[{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"551abbb1-2377-fac5-a867-cb3fbd667dbe","name":"Get Article : 500 DataNotFoundException","description":"","url":"http://localhost:8080/dms/rest/articles/4561","method":"GET","headers":"Accept: application/json\n","data":[{"key":"title","value":"","type":"text"},{"key":"products","value":"Temodal®, MSD Sharp & Dohme GmbH|TEMOZO-cell, cell pharm GmbH|Temozolomid HEXAL, Hexal AG|Temozolomid Hospira, Hospira Deutschland GmbH|Temozolomid-ratiopharm, ratiopharm GmbH|Temozolomid ribosepharm, Hikma Pharma GmbH|Temozolomid TEVA, TEVA GmbH|Temomedac, medac GmbH","type":"text"},{"key":"ingredients","value":"ing1|ing2|ing3","type":"text"},{"key":"companies","value":"MSD Sharp & Dohme GmbH|cell pharm GmbH|Hexal AG","type":"text"},{"key":"articledate","value":"06.11.2015","type":"text"},{"key":"description","value":"Die Hersteller Temozolomid-haltiger Arzneimittel  informieren in diesem Rote-Hand-Briefüber Fälle von Leberschäden, einschließlich letalem Leberversagen bei Patienten, die mit Temozolomid behandelt wurden. Deshalb  gelten ab sofort spezielle Empfehlungen zur Überwachung der Leberfunktion: -Die Leberwerte sollen vor der Behandlung und nach jedem Behandlungszyklus bestimmt werden. -Bei Patienten mit einem 42-tägigen Zyklus sollen die Werte auch in der Mitte des Behandlungszyklus bestimmt werden. -Bei abnormen Leberwerten ist das Nutzen-Risiko-Verhältnis vor und während der Behandlung sorgfältig abzuwägen und ggf. nicht begonnen oder abgebrochen werden.","type":"text"},{"key":"originalfile","value":"Rote-Hand-Brief zu Temozolomid.pdf","type":"text"},{"key":"sources","value":"Rote Hande Magazine|AWFS Magazine|Hexal AG","type":"text"},{"key":"friendlyurl","value":"http://www.gelbe-liste.de/c/document_library/get_file?uuid=319cf68f-6ebd-4c47-b533-f1786cc029b3&groupId=84530","type":"text"},{"key":"htmltitel","value":"not known html title","type":"text"},{"key":"keywords","value":"Rote Hande|Temozolomid|Hexal","type":"text"},{"key":"rights","value":"all","type":"text"}],"dataMode":"urlencoded","timestamp":0,"version":2,"time":1447676687379},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"5b76a55a-c1d5-b503-ce9d-e742a3335189","name":"updateArticle : 200 OK","description":"","url":"http://localhost:8080/dms/rest/articles/456","method":"PUT","headers":"Accept: application/json\nContent-Type: application/json\n","data":"{\n    \"authors\": [],\n    \"bodyPictures\": [],\n    \"friendlyUrl\": \"http://localhost:8080/dms/rest/articles/456\",\n    \"htmlTitle\": \"Article Two NOW updated\",\n    \"relations\": [],\n    \"rights\": [],\n    \"searchable\": false,\n    \"version\": 0\n}","dataMode":"raw","timestamp":0,"version":2,"time":1447324018063},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"7d2d21c9-9cce-bdcf-5415-133e4fc6705f","name":"Delete Relation : 200 Ok","description":"","url":"http://localhost:8080/dms/rest/articles/123/relations/12/95123/","method":"DELETE","headers":"Accept: application/json\n","data":[],"dataMode":"urlencoded","timestamp":0,"version":2,"time":1447690432010},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"84067e7e-f276-9580-7fb4-4079ed20b57c","name":"Get Articles","description":"","url":"http://localhost:8080/dms/rest/articles?offset=30&limit=15","method":"GET","headers":"Accept: application/json\n","data":"{\n    \"created\": \"2015-11-11T12:57:25.733+01:00\",\n    \"id\": 45576,\n    \"name\": \"New Title for 456: at 13:01\"\n}","dataMode":"raw","timestamp":0,"version":2,"time":1447316035329},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"8abbc7d1-27f8-3389-a5dd-c123bcab089c","name":"deleteArticle : 202 Accepted","description":"","url":"http://localhost:8080/dms/rest/articles/456","method":"DELETE","headers":"Accept: application/json\n","data":"","dataMode":"raw","timestamp":0,"version":2,"time":1447676407115},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"8c2dac13-48ba-4b43-bccc-fc5ccb7882fd","name":"Add Relation : 200 Ok","description":"","url":"http://localhost:8080/dms/rest/articles/123/relations","method":"PUT","headers":"Accept: application/json\n","data":[{"key":"objecttypeid","value":"12","type":"text"},{"key":"objectid","value":"95123","type":"text"}],"dataMode":"urlencoded","timestamp":0,"version":2,"time":1447686587243},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"8da11c82-f2d3-1081-a03c-4652cf514e26","name":"GetArticle : JSON","description":"","url":"http://localhost:8080/dms/rest/articles/456","method":"GET","headers":"Accept: application/json\n","data":"{\n    \"created\": \"2015-11-11T12:57:25.733+01:00\",\n    \"id\": 45576,\n    \"name\": \"New Title for 456: at 13:01\"\n}","dataMode":"raw","timestamp":0,"version":2,"time":1447316572232},{"collectionId":"94b2ceae-8bac-44c4-4aa5-43d15e57660a","id":"b0ac2533-1e85-8562-2481-1a2003cb2a6a","name":"Post Article : 201 Created","description":"","url":"http://localhost:8080/dms/rest/articles","method":"POST","headers":"Accept: application/json\n","data":[{"key":"title","value":"Title Goes here","type":"text"},{"key":"products","value":"Temodal®, MSD Sharp & Dohme GmbH|TEMOZO-cell, cell pharm GmbH|Temozolomid HEXAL, Hexal AG|Temozolomid Hospira, Hospira Deutschland GmbH|Temozolomid-ratiopharm, ratiopharm GmbH|Temozolomid ribosepharm, Hikma Pharma GmbH|Temozolomid TEVA, TEVA GmbH|Temomedac, medac GmbH","type":"text"},{"key":"ingredients","value":"ing1|ing2|ing3","type":"text"},{"key":"companies","value":"MSD Sharp & Dohme GmbH|cell pharm GmbH|Hexal AG","type":"text"},{"key":"articledate","value":"06.11.2015","type":"text"},{"key":"description","value":"Die Hersteller Temozolomid-haltiger Arzneimittel  informieren in diesem Rote-Hand-Briefüber Fälle von Leberschäden, einschließlich letalem Leberversagen bei Patienten, die mit Temozolomid behandelt wurden. Deshalb  gelten ab sofort spezielle Empfehlungen zur Überwachung der Leberfunktion: -Die Leberwerte sollen vor der Behandlung und nach jedem Behandlungszyklus bestimmt werden. -Bei Patienten mit einem 42-tägigen Zyklus sollen die Werte auch in der Mitte des Behandlungszyklus bestimmt werden. -Bei abnormen Leberwerten ist das Nutzen-Risiko-Verhältnis vor und während der Behandlung sorgfältig abzuwägen und ggf. nicht begonnen oder abgebrochen werden.","type":"text"},{"key":"originalfile","value":"Rote-Hand-Brief zu Temozolomid.pdf","type":"text"},{"key":"sources","value":"Rote Hande Magazine|AWFS Magazine|Hexal AG","type":"text"},{"key":"friendlyurl","value":"http://www.gelbe-liste.de/c/document_library/get_file?uuid=319cf68f-6ebd-4c47-b533-f1786cc029b3&groupId=84530","type":"text"},{"key":"htmltitel","value":"not known html title","type":"text"},{"key":"keywords","value":"Rote Hande|Temozolomid|Hexal","type":"text"},{"key":"rights","value":"all","type":"text"},{"key":"name","value":"mypdfarticle","type":"text"},{"key":"extension","value":"pdf","type":"text"}],"dataMode":"urlencoded","timestamp":0,"version":2,"time":1447677331437}]}